PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 1, 2026Anticancer Research0 citations

A Real-World Evaluation of Health-Related Quality of Life Using the EQ-5D-5L Instrument in Patients Undergoing Radiotherapy for Prostate Cancer

TST. SpraveSFS. FauserPPPetros Paplomatas

Key Points

  • This study aims to evaluate health-related quality of life trajectories using the EQ-5D-5L instrument in prostate cancer patients undergoing radiotherapy.
  • Prospective assessment of 262 prostate cancer patients using the EQ-5D-5L questionnaire
  • Evaluated at baseline, treatment completion, and final follow-up
  • Measured health-related quality of life using health index and visual analogue scale
  • Identified predictors of outcomes using multiple linear regression models
  • Categorized meaningful changes according to minimal important difference thresholds.
  • Mean baseline health index scores were high, ranging from 0.91 to 0.95 across treatment groups
  • Health-related quality of life remained stable or improved at follow-up
  • Hypofractionated patients showed a greater improvement in health-related quality of life
  • Regression analysis confirmed baseline scores as strong predictors of post-treatment outcomes
  • Adjusted models improved predictive performance, especially for health index.

Abstract

Background/Aim: Prostate cancer (PC) is increasingly treated with curative intent, making health-related quality of life (HRQOL) a key outcome. This prospective study evaluated the EQ-5D-5L instrument based HRQOL trajectories in PC patients undergoing radiotherapy (RT) to assess the instrument’s responsiveness, determine meaningful changes, and strengthen the evidence on patient-centered outcomes in routine care. Patients and Methods: A total of 262 patients undergoing curative RT were prospectively assessed using the EQ-5D-5L questionnaire at baseline, treatment completion, and final follow-up. HRQOL was evaluated using the health index (HI) and visual analogue scale (VAS), with clinically meaningful changes categorized according to validated minimal important difference (MID) thresholds. Multiple linear regression models were constructed to identify predictors of HI and VAS outcomes, with baseline HRQOL values emerging as the strongest determinants of post-treatment scores. Results: The study cohort was stratified into primary, adjuvant, and salvage RT groups. Mean baseline HI scores were high across groups, ranging from 0.91 to 0.95, and remained stable or improved at follow-up. VAS scores demonstrated similar stability, with final follow-up values ranging from 77.0 to 83.0 across treatment groups. Hypofractionated patients showed superior HRQOL trajectories, with 40% HI and 80% VAS improvement at follow-up, compared to 25% and 29% in normofractionated patients, respectively. Longitudinal analyses revealed favorable HRQOL preservation, particularly in salvage RT, where HI improved from 0.93 to 0.96. Regression analysis confirmed baseline HRQOL values as the strongest predictors of both HI and VAS outcomes (p2=0.514). Conclusion: The sustained HRQOL, particularly in adjuvant and salvage settings, supports the role of RT in multimodal strategies.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Sprave et al. (2026) studied this question.

synapsesocial.com/papers/69a3d887ec16d51705d2f83ehttps://doi.org/10.21873/anticanres.18065
Ask AI
Helpful
Bookmark
Share
View Full Paper